© Rosalind Scientific LLC 2018-2022
© Rosalind Scientific LLC, 2018-2022
New Drug Hunter content, featured events and job postings straight to your inbox. Trusted by >3,500 drug hunters worldwide, unsubscribe anytime.
<< Back to April
oral once-daily sGC activator
Ph. II for CKD + diabetic neuropathy
from cell-based HTS + opt
J. Med. Chem., Apr. 19, 2021
Bayer AG, Wuppertal, DE
The Bayer soluble guanylate cyclase (sGC) activator, BAY 1101042 (runcaciguat), is a once-daily (50 mg), oral clinical candidate in Ph. II for chronic kidney disease and diabetic retinopathy. sGC is…
Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.